NIIMBL, established under the University of Delaware by the Department of Commerce, focuses on enabling more efficient and flexible manufacturing capabilities for existing and emerging biopharmaceutical products, and developing a world-leading biopharmaceutical manufacturing workforce and their roadmap for biomanufacturing. Their roadmap for the manufacturing needs and propose a vision of the future for three key topics areas: (1) Vaccines; (2) Antibody-Drug Conjugates (ADC) and Bi-specific Antibodies; (3) Gene Therapies. Project calls are issues each year, with the Project Call 3.1 deadline on September 10, 2019. View NIIMBL’s various achievements and milestones in their 2018-19 annual report. For more information on membership, please visit